Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement (RCA) focused on the use of real-world evidence (RWE) to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to address key regulatory questions about testing and treatment patterns, dosing and safety, and outcomes in oncology, with a focus on precision medicine.Methods to Derive RWE From Multiple
Read More
SHUH, Syapse to Build South Korea’s First Real-World Data Sharing Network for Precision Oncology Hospitals
SNUH and Syapse will collaboratively work towards building South Korea’s first real-world data-sharing network for leading precision oncology hospitals in the region. Syapse, a company accelerating precision medicine through insights derived from its global health system network, and Seoul National University Hospital (SNUH), a South Korea-based hospital, today announced that they have extended their partnership with a new multi-year agreement. As part of their partnership, SNUH and Syapse will
Read More
Pfizer, Syapse Partner on Oncology Precision Medicine Using Real-World Evidence (RWE)
Syapse, a San Francisco, CA-based precision medicine company, today announced that it has entered into a strategic collaboration with Pfizer to advance cancer outcomes research using real-world evidence (RWE) toward the ultimate goal of improving patient health. This collaboration will initially focus on the molecular testing and therapy choices on precision oncology journeys in the healthcare system setting.Syapse NetworkThe Syapse Network enables health systems and their providers to learn
Read More
Amgen, Syapse Partner to Develop Observational Research Analytics for Precision Oncology
Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology. Under the terms of the collaboration, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.Generates Insights from Real-World Evidence for Potential Use in Regulatory FilingsThis effort will identify existing patients within
Read More
Syapse to Utilize NCCN Biomarkers Compendium for More Personalized Care
New partnership between National Comprehensive Cancer Network and Syapse will augment health information technology around cancer care. The National Comprehensive Cancer Network(NCCN) announced a new agreement with Syapse, a precision medicine company, to expand the use of best practices in precision medicine when treating people with cancer. Syapse delivers solutions for scaling enterprise precision oncology programs. For Syapse, the data contained in theNCCN Biomarkers Compendium will
Read More
Syapse Precision Medicine Council Launches to Advance Precision Oncology Adoption
Syapse, a San Francisco, CA-based precision medicine company, announced today the formation of the Syapse Precision Medicine Council, a group of oncology, operations, and research leaders from health systems dedicated to advancing precision oncology adoption through sharing best practices.Inaugural members include Henry Ford Health System, Catholic Health Initiatives and Dignity Health (the Precision Medicine Alliance), Providence St. Joseph Health, Aurora Health Care, and the University of
Read More
Medidata, Syapse Partner to Democratize Access to Oncology Clinical Trials
Medidata, a provider of cloud-based technology and data analytics for clinical research, and Syapse, a precision medicine solutions provider, have announced a new partnership to transform oncology clinical trials for the age of precision medicine. As part of the new partnership, Medidata and Syapse will jointly develop a portfolio of solutions to make it easier for cancer patients to access potentially life-saving clinical trials,Partnership DetailsThe partnership will initially build products
Read More
Syapse Expands Precision Medicine to Asia Through Partnership With Health System
Syapse, a precision medicine company, announced today it is expanding to Asia through new partnerships with Seoul National University Hospital (SNUH), the premier hospital in Korea, and Megazone, a cloud-specialized IT company.Syapse and SNUH are launching a precision oncology program to improve cancer care in Korea, with the support of Megazone’s innovative cloud services. SNUH, one of the largest health systems in South Korea, is the first health system outside the U.S. to use the Syapse
Read More
Syapse Lands $30M to Expand Precision Oncology to More Healthcare Providers
Syapse, a a San Francisco, CA-based provider of precision oncology solutions, has raised $30 million in Series D financing. Participants include existing investors Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics, and Social Capital, as well as new investors Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund, and Roche Venture Fund.The company plans to use the latest round of funding to expand operations and bring its precision
Read More
Aurora Cancer Care Launches Precision Medicine Program To Help Patients Gain More Access to Clinical Trials
Aurora Cancer Care, a not-for-profit health care provider in Wisconsin and northern Illinois is launching a precision medicine program powered by Syapse, a provider of precision oncology solutions. The new oncology precision medicine program will help physicians and researchers provide more care options for patients whose cancer is resistant to conventional treatment options like radiation and chemotherapy.The new multi-disciplinary Oncology Precision Medicine Clinic will be located inside
Read More